Latest News | Cipla Gets USFDA Nod for Generic Cancer Drug

New Delhi, Apr 11 (PTI) Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug.

The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing.

Also Read | Bodoland Lottery Result Today, April 11, 2025: Assam State Lottery Sambad Friday Lucky Draw Results Declared, Check Winners List With Ticket Numbers.

Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial.

Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas.

Also Read | Kolkata Fatafat Result Today: Kolkata FF Result for April 11, 2025 Declared, Check Winning Numbers and Result Chart of Satta Matka-Type Lottery Game.

The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said.

Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)